Invention Grant
- Patent Title: Broadly-neutralizing anti-HIV antibodies
-
Application No.: US17470184Application Date: 2021-09-09
-
Publication No.: US11649276B2Publication Date: 2023-05-16
- Inventor: Hugo Mouquet , Michel Nussenzweig , Pamela J. Bjorkman , Louise Scharf
- Applicant: The Rockefeller University , California Institute of Technology
- Applicant Address: US NY New York
- Assignee: The Rockefeller University,California Institute of Technology
- Current Assignee: The Rockefeller University,California Institute of Technology
- Current Assignee Address: US NY New York; US CA Pasadena
- Agency: Fox Rothschild LLP
- The original application number of the division: US16507867 2019.07.10
- Main IPC: C07K16/10
- IPC: C07K16/10 ; A61K39/42 ; A61K45/06 ; A61K39/00
Abstract:
The present invention relates to anti-HIV antibodies. Also disclosed are related methods and compositions. HIV causes acquired immunodeficiency syndrome (AIDS), a condition in humans characterized by clinical features including wasting syndromes, central nervous system degeneration and profound immunosuppression that results in life-threatening opportunistic infections and malignancies. Since its discovery in 1981, HIV type 1 (HIV-1) has led to the death of at least 25 million people worldwide.
Public/Granted literature
- US20220002390A1 Broadly-Neutralizing ANTI-HIV Antibodies Public/Granted day:2022-01-06
Information query
